All adult patients with chronic myeloid leukaemia in any phase (chronic, accelerated or blastic) who undergo allogeneic stem cell transplantation between 01/01/2010 and 30/09/2013 and have been previously treated with Nilotinib or Dasatinib, regardless of their response to these drugs. 

NCT02222272_inc_T1
Condition
chronic myeloid leukaemia
NCT02222272_inc_T2
Procedure
allogeneic stem cell transplantation
NCT02222272_inc_T3
Temporal
between 01/01/2010 and 30/09/2013
NCT02222272_inc_T4
Drug
Nilotinib
NCT02222272_inc_T5
Drug
Dasatinib
NCT02222272_inc_T6
Temporal
previously
NCT02222272_inc_T7
Scope
Nilotinib or Dasatinib
NCT02222272_inc_T8
Qualifier
chronic
NCT02222272_inc_T9
Qualifier
accelerated
NCT02222272_inc_T10
Qualifier
blastic
NCT02222272_inc_T11
Qualifier
any phase
NCT02222272_inc_T12
Scope
chronic, accelerated or blastic
NCT02222272_inc_T13
Person
adult